[Effects of arsenic trioxide on the autoimmunity and survival time in BXSB lupus mice].
OBJECTIVE
To investigate the effect of arsenic trioxide (ATO) on the autoimmunity and survival time in BXSB lupus mice.


METHODS
The model BXSB lupus mice were randomly divided into two groups equally, the ATO treated group and the control group, 17 in each group. Mice in the ATO group were given intraperitoneal injection of ATO at the daily dose of 0.4 mg/kg, once every other day for 105 days or 90 days, respectively, and the observation lasted for 210 days. The survival time between the two groups was compared; the serum levels of anti-dsDNA and IgG were detected by enzyme-linked immunosorbent assay (ELISA), and the interferon-gamma (IFN-gamma) mRNA expression in renal and spleen tissue were measured by reverse transcriptase polymerase chain reaction (RT-PCR) technique.


RESULTS
Till the 210th day, the total number of death was 8 in the ATO treated group and 13 in the control group, comparison between the two groups showed significantly different (chi2 = 4.20, P < 0.05). The mean OD value of serum anti-dsDNA antibody was lower in the ATO group (0.392 +/- 0.087) than that in the control group (0.566 +/- 0.080, P < 0.001). The serum level of IgG on day 105 in the ATO group was significantly lower than that in the control group and before treatment (P < 0.05). The expression of IFN-gamma mRNA in spleen tissue and renal tissue in the ATO group and the control group was 0.540 +/- 0.300 and 0.338 +/- 0.163, 2.320 +/- 0.522 and 0.588 +/- 0.104 (P < 0.05 and P < 0.01 respectively).


CONCLUSIONS
ATO can prolong the survival time of BXSB lupus mice, decrease the peripheral level of anti-dsDNA antibody and IgG expression, inhibit the over-expression of IFN-gamma mRNA in spleen and kidney tissues.
Xia
Xiao-ru
XR
Department of Rheumatology, First Affiliated Hospital of Wenzhou Medical College, Zhejiang. zhuxiaochun@hospl.ac.cn
Lin
Su-xian
SX
Zhou
Yan
Y
D000818:Animals; D000974:Antibodies, Antinuclear / Q000097:blood; D000077237:Arsenic Trioxide; D001152:Arsenicals / Q000008:administration & dosage / Q000627:therapeutic use*; D015551:Autoimmunity / Q000187:drug effects*; D004797:Enzyme-Linked Immunosorbent Assay; D007074:Immunoglobulin G / Q000097:blood; D007274:Injections, Intraperitoneal; D007371:Interferon-gamma / Q000235:genetics; D007668:Kidney / Q000187:drug effects / Q000378:metabolism; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy* / Q000235:genetics / Q000276:immunology; D051379:Mice; D010087:Oxides / Q000008:administration & dosage / Q000627:therapeutic use*; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D011897:Random Allocation; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013154:Spleen / Q000187:drug effects / Q000378:metabolism; D016019:Survival Analysis
D000974:Antibodies, Antinuclear; D001152:Arsenicals; D007074:Immunoglobulin G; D010087:Oxides; D012333:RNA, Messenger; D007371:Interferon-gamma; D000077237:Arsenic Trioxide